<DOC>
	<DOCNO>NCT00752726</DOCNO>
	<brief_summary>The purpose study determine 24 week weight loss program orlistat 60 mg produce great change body composition compare placebo .</brief_summary>
	<brief_title>Effect Orlistat Body Composition</brief_title>
	<detailed_description>Large amount VAT ( adipose tissue surround viscera organ ) , know associate increase risk heart disease diabetes . Orlistat ( tetrahydrolipstatin THL ) inhibit gastrointestinal lipase reduces absorption dietary fat . The purpose study determine 24 week weight loss program orlistat 60 mg would produce great change adipose tissue depot ( specifically VAT ) compare placebo . This study use Echo MRI technology across multiple site measure total fat mass . EchoMRI non invasive method ideally suit study track change human body composition time , measure time less 3 minute radiation exposure .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>Aged 1860 year inclusive Body Mass Index ( BMI ) : BMI range 25.034.9 kg/m^2 Waist circumference : Females : &gt; 35 inch Males : &gt; 40 inch Diet : 1 . Normal eating habit , consume 3 meal day ( breakfast , lunch dinner ) 2 . Willing follow hypocaloric diet study achieve weight loss 3 . Willing take daily multivitamin duration study . General Health : Good general health ( opinion investigator ) clinically significant relevant abnormality medical history physical examination Pregnant and/ Breastfeeding woman Diet/Exercise : Currently special diet fulfill dietary requirement study . Smoking History : ) Smoking cessation within past 6 month b ) Current Smokers Allergy/Intolerance : Known suspected intolerance hypersensitivity study material study food ( closely relate compound ) state ingredient . Medication : ) Currently take medication weight loss appetite control . b ) Previous Xenical® ( orlistat ) alli® use within 3 month screen date c ) Currently take medication supplement influence intestinal transit time stool formation parameter influence cramp ( e.g. , Anticholinergics ( atropine ) cholinergics ( physostigmine ) , phenothiazine , tricyclic antidepressant , opioid analgesic ( include loperamide ) , calcium channel antagonist , clonidine , cisapride , octreotide . Also , laxative antidiarrheal product ) . ) Currently take withdraw past 6 month drug significant impact body weight ( e.g . serotoninergically act drug , antidepressant , central adrenergically act drug , drug inhibit digestion absorption , appetite suppressant , metformin ) e ) Currently take Cyclosporine , Warfarin Amiodarone HCL Disease/Surgery : ) History gastrointestinal disease ( e.g. , irritable bowel syndrome , diarrhea , inflame bowel , steatorrhea/fat malabsorption , hemorrhoid , incontinence , pancreatitis ) . b ) History psychological disorder , include eat disorder anorexia nervosa bulimia c ) History neurological disorder ( e.g . seizure , parkinson 's disease , Alzheimer 's disease ) ) History hypo/hyperthyroidism unless euthyroid control stable dose medication least 6 month . e ) History surgery weight loss f ) Uncontrolled hypertension g ) Heart Disease h ) Diabetes Mellitus ( Type 1 2 ) ( Fasting Blood Glucose &gt; 126 mg/dL ) Participant know history panic attack and/or claustrophobia condition preclude safe EchoMRI , CT scan modality accord local guideline , ( e.g. , pacemaker , hear aid , metallic body pierce and/or metal implant ) opinion Investigator participant exceed size limitation instrument . Participant weight loss gain great equal 3 kg 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>overweight , orlistat , body composition</keyword>
</DOC>